All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Sonnet Biotherapeutics Holdings Inc. has completed two IND-enabling toxicology studies in nonhuman primates (NHPs) using its lead bifunctional therapeutic candidate, SON-1210.
